Press Releases

MONACO, July 27, 2026 (GLOBE NEWSWIRE) -- Costamare Inc. ("Costamare" or the "Company") (NYSE:CMRE) today reported unaudited financial results for the second quarter and six-month period ended June 30, 2026. PROFITABILITY AND LIQUIDITY Q2 2026 Adjusted Net Income from Continuing operations1 available to common stockholders2 of $75.1 million ($0.62 per share).Q2 2026 Net Income from Continuing operations1 available to common stockholders of $77.4 million ($0.64 per share).Q2 2026 liquidity of $423.0 million3. II. NEW BILATERAL FINANCING AGREEMENTS OF $1.3 BILLION WITH A NUMBER OF LEADING US, EUROPEAN AND ASIAN BANKS4 Concluded new financing agreements for $920 million and refina

Second Quarter Highlights Net income of $27.8 million, or $0.76 per diluted share; return on average assets ("ROAA") of 1.66%; return on average stockholders' equity ("ROAE") of 14.73%; and return on average tangible common equity ("ROATCE")(1) of 17.69%Adjusted net income(1) of $28.5 million, or $0.78 per diluted share; adjusted ROAA(1) of 1.70%; adjusted ROAE(1) of 15.09%; and adjusted ROATCE(1) of 18.13%Asset quality remained strong with nonperforming assets to total assets of 0.15% and net recoveries to average loans of 0.01%, on an annualized basisNet interest margin increased 12 basis points to 4.32% and net interest margin (tax-equivalent basis)(1) increased 13 basis points to 4.38%

NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- Keel Infrastructure Corp. (NASDAQ:KEEL, TSX:KEEL) ("Keel Infrastructure" or "Keel"), a North American digital infrastructure and energy company, will report its second quarter 2026 financial results on Monday, August 10 before the market opens. Management will host a conference call on the same day at 8:00 am Eastern. Q2 2026 materials will be available before the call and can be accessed on the ‘Quarterly Results’ section of the Keel investor site. The live webcast and a webcast replay of the conference call can be accessed here. To access the call by telephone, register here to receive dial-in numbers and a unique PIN to join the call. About

Results provide opportunity to expand CLDN18.2 positivity to ≥25% expression, representing approximately 60% of patients in this setting CLARITY-Gastric01 is the first Phase III trial to show overall survival benefit with an anti-CLDN18.2 ADC in this setting First pivotal readout from AstraZeneca’s wholly owned ADC portfolio Positive high-level results from the CLARITY-Gastric01 global Phase III trial showed that sonesitatug vedotin (Sone-Ve) demonstrated a statistically significant and highly clinically meaningful improvement in overall survival (OS) in 2nd and later-line Claudin 18.2-positive advanced gastric cancers versus investigator’s choice of therapy. The trial included patien

Qnity Electronics, Inc. ("Qnity") (NYSE:Q), a premier technology solutions leader across the semiconductor value chain, announced today it has received the 2026 Distinguished Contribution Award by Zhen Ding Technology Group ("Zhen Ding") (4958-TW), one of the world’s leading printed circuit board manufacturers. The award recognizes outstanding partner performance across materials, equipment, and services, underscoring Qnity’s commitment to making tomorrow’s technologies possible by partnering closely with customers to solve increasingly complex challenges through materials innovation. As advancements in AI, high-performance computing, and advanced connectivity continue to drive increase

NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- Prospect Enhanced Yield Fund ("PENF" or the "Fund") announced today that the Fund’s Board of Directors has declared a $0.04775 increase in the monthly cash shareholder distributions for July, August, and September 2026. These distributions represent the 10th, 11th, and 12th monthly distributions paid by the Fund. As a result of this announcement, the annualized total cash distribution is $2.85 per share (11.5% annualized rate based on the June 30, 2026 net asset value), for distributions with record dates between July 30, 2026 and September 29, 2026 based on the June 30, 2026 net asset value of $24.87 per common share. The cash distribution wil

– Leadership updates come as Precision advances its lead programs, PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy – Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced changes to its senior leadership team. Alex Kelly, currently Chief Financial Officer, has been promoted to the newly created role of Chief Operating Officer where he will oversee all key customer-facing functions. Naresh Tanna, currently Vice President of Investor Relations and Chief of Staff to the CEO, has been promoted to Ch

NEW HAVEN, Conn., July 27, 2026 /PRNewswire/ -- Biohaven Ltd. and/or its wholly owned subsidiaries ("Biohaven") (NYSE:BHVN) and Yale University ("Yale") today announced that a federal jury in the U.S. District Court for the District of Delaware returned a verdict in their favor in the trade secret misappropriation and breach of contract litigation against Avilar Therapeutics, Inc. ("Avilar") and RA Capital Management GP, LLC ("RA Capital"). The jury found that Avilar and RA Capital willfully and maliciously misappropriated a Yale trade secret relating to its "MODA" targeted protein degradation platform, and that RA Capital sepa

David Wiens Appointed Chief Executive Officer and Director and Shane Parrow Appointed President, Chief Operating Officer, and DirectorIncoming CEO David Wiens to Invest Through One-Time Private Placement in Connection with AppointmentKarl Hanneman to Continue as Strategic Advisor and Director, supporting a seamless leadership transitionNew leadership team combines extensive capital markets, project financing, Alaska operations and mine development experience as Company positioned to advance Livengood through feasibility, permitting, financing, and developmentVANCOUVER, BC, July 27, 2026 /CNW/ -- International Tower Hill Mines Ltd. (the "Company") - (TSX:ITH) (NYSE:THM) is pleased to announce

TORONTO, July 27, 2026 /CNW/ -- A2Z Cust2Mate Solutions Corp. (NASDAQ:AZ), a global leader in smart retail technology, today announced that the company will release financial results for the second quarter ended June 30, 2026, after market close on Wednesday, August 12, 2026. A conference call to discuss the results will be held at 5:00 PM Eastern Time on the same day. Conference Call DetailsThe conference call may be accessed by dialing 1-877-317-6789 (U.S. toll-free), +972 3-374-1008 (Israel Tel Aviv), or 1-412-317-6789 (International). The live webcast of the call can be accessed using the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=s59AphpyAbout A2Z Cus

2026 Quarter Highlights Total revenue of $551.6 million, net income of $79.6 million, and Adjusted EBITDA of $185.7 million, up year-over-year 0.7%, 33.9% and 14.7%, respectively Record oil & gas royalty revenues of $46.3 million, up 30.5% year-over-year Secured 21.2 million additional committed and priced sales tons over the 2026 – 2031 time period Distributable Cash Flow of $108.2 million and Distribution Coverage Ratio of 1.39x both improved by 39.0% sequentially Declares quarterly cash distribution of $0.60 per unit, or $2.40 per unit annualized On July 1, 2026, completed our $206.2 million acquisition of oil & gas mineral interests, adding 48,500 net royalty acres to

WARSAW, Ind., July 27, 2026 (GLOBE NEWSWIRE) -- Lakeland Financial Corporation (Nasdaq Global Select/LKFN), parent company of Lake City Bank, today reported record second quarter net income of $28.4 million for the three months ended June 30, 2026, which represents an increase of $1.5 million, or 5%, compared to net income of $27.0 million for the three months ended June 30, 2025. Diluted earnings per share of $1.13 for the second quarter of 2026 also represents a record second quarter performance and increased $0.09, or 9%, compared to $1.04 for the second quarter of 2025. On a linked quarter basis, net income increased $2.0 million, or 7%, from $26.5 million. Diluted earnings per share i

Proposed NSM Labs name reflects expansion across drones, defense, aerospace, critical minerals and infrastructure Mobix Labs, Inc. (NASDAQ:MOBX), a provider of advanced technologies for defense, aerospace and other mission-critical markets, today announced that its Board of Directors has approved a proposal to change the Company’s corporate name to NSM Labs, Inc., subject to stockholder approval at an upcoming stockholder meeting. NSM stands for National Security Matters. A Defining Transformation The proposed NSM Labs name is intended to align the Company’s public identity with its expanding strategy to build a diversified national-security technology platform spanning defense and

Growth momentum continues. On track to deliver ambition of $80 billion in Total Revenue in 2030 AstraZeneca: Revenue and EPS summary   H1 2026 % Change Q2 2026 % Change   $m Actual CER1 $m Actual CER - Product Sales 28,896 8 5 14,510 5 4 - Alliance Revenue 1,699 31 29 874 34 33 Product Revenue 30,595 9 6 15,384 6 5 Collaboration Revenue 77 (6) (9) - n/m n/m Total Revenue 30,672 9 6 15,384 6 5

– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutinib in PAH –– Gossamer Reacquires Worldwide Rights to Seralutinib, Aligning Global Commercial Control for a Potential First-in-Class Opportunity –– Stockholders Approved Proposals Related to Convertible Note Exchange and Reverse Stock Split, Supporting a Strengthened Capital Structure –– Cash, Cash Equivalents and Marketable Securities Totaled Approximately $57 Million as of June 30, 2026 –Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arteri

Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the completion of patient enrollment in its U.S. 510(k) pivotal study evaluating the PRESERFLO™ MicroShunt in adult patients with primary open-angle glaucoma (POAG) who failed previous medical and surgical treatment. The PRESERFLO MicroShunt is a novel, ab-externo glaucoma drainage device designed to lower intraocular pressure (IOP). Constructed from a proprietary, biocompatible material known as SIBS [poly(styrene-block-isobutylene-block-styrene)], the PRESERFLO MicroShunt is an 8.5

The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to placebo at Week 5 with an effect size of 0.37 (LS mean difference vs PBO -4.5, p=0.015) Cognitive performance was improved (ES=0.51, p=0.041) in those with baseline cognitive impairment on a prespecified secondary endpoint 210/3 mg BID dose also achieved significant separation on key secondary endpoints, including CGI-S (ES=0.48, p=0.002) and PANSS Positive Marder Factor (ES=0.39, p=0.012) ML-007C-MA was generally well tolerated at both doses studied, with no serious or drug-related severe advers

Offer of $27.34 Per Share, Comprised of $24.80 in Cash and One Diana Share, Remains on the Table Genco's Characterization of Advisor Engagement to Discuss the Price, Terms and Structure of Diana’s Proposal Is False More Than Five Weeks After Diana's Most Recent Offer, the Genco Board Continues to Use Stall Tactics to Avoid Real Engagement Diana Terminates Tender Offer to Eliminate Genco's Latest Excuse for Failing to Engage Substantively ATHENS, Greece, July 27, 2026 (GLOBE NEWSWIRE) -- Diana Shipping Inc. (NYSE:DSX) ("Diana" or "the Company"), a global shipping company specializing in the ownership and bareboat charter-in of dry bulk vessels that is the largest shareholder of Genco Sh

NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- Marex Group Limited ((‘Marex’ or the ‘Group’, NASDAQ:MRX), the diversified global financial services platform, today announced that it will release its fiscal 2026 second quarter results before market open on Wednesday, August 12, 2026. The earnings release and supplementary materials will be available through the "Investors" section of the Marex website at https://ir.marex.com/. A conference call to discuss the results will take place at 9am ET the same day. If you would like to attend the live conference call you can access it here:https://events.q4inc.com/attendee/240823774 About Marex: Marex Group Limited (NASDAQ:MRX) provides market acces

BERKELEY HEIGHTS, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated, commercial-stage biotechnology company, today announced that it will host a conference call and webcast to report second quarter 2026 financial results and operational highlights on Monday, August 10, 2026, at 8:30 a.m. ET. To listen to the conference call, register at this link. To view the webcast, register at this link. A replay will be available under "IR Events" in the Investors section of the Company’s website at https://ir.tonixpharma.com/news-events/ir-events. Tonix Pharmaceuticals Holding Corp.Tonix Pharmaceuticals* is